CJC-1295 and Rivaroxaban Interaction: Safety, Mechanism, and Clinical Monitoring
At a glance
- Approval status of CJC-1295 / Not approved in any country FDA searched [1]
- Human studies of CJC-1295 / Three, all of the DAC form, all in healthy volunteers [1]
- Study of CJC-1295 plus rivaroxaban / We found none
- Rivaroxaban bleeding warning / Label: can cause serious and fatal bleeding [2]
- Rivaroxaban half-life / 5 to 9 hours in healthy young adults [3]
- St John's wort plus rivaroxaban / AUC ratio 0.76 after 2 weeks of extract in 12 volunteers [4]
Is there a known interaction between CJC-1295 and rivaroxaban?
We found no published study that gave CJC-1295 and rivaroxaban to the same people. CJC-1295 is not an FDA-approved drug, and FDA found no approved product containing it in the countries it searched [1]. Rivaroxaban exposure is sensitive to CYP3A and P-glycoprotein activity: in 12 healthy volunteers, two weeks of a hyperforin-containing St John's wort extract lowered rivaroxaban AUC to a geometric mean ratio of 0.76 (90% CI 0.70-0.82) and factor Xa inhibition to 0.80 [4]; a second study in 12 volunteers found AUC and peak concentration 25% lower [5]. Whether CJC-1295 affects those pathways has not been established, so the lack of data does not show that the pair is safe.
What the human data on CJC-1295 consist of
CJC-1295 is an investigational long-acting growth hormone-releasing hormone analogue first described in 2005 [8]. FDA identified three published human studies of it, all of the DAC form and all in healthy volunteers [1]. In the Teichman trials, one subcutaneous injection raised mean growth hormone 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9 to 11 days, with an estimated half-life of 5.8 to 8.1 days [6]. Reported effects included injection-site reactions (about 70% of treated subjects in the first trial and all of them in the second), headache at 63% versus 14% on placebo in the first trial, and flushing, warmth and transient low blood pressure in about 30% of treated subjects in the first trial [1][6]. No trial tested the form sold as CJC-1295 without DAC, and the studies measured hormone levels rather than health outcomes [1][6].
What the rivaroxaban label warns about, and what FDA says about CJC-1295
The Xarelto label says it can cause serious and fatal bleeding, and that drugs which impair hemostasis raise the risk, including aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs [2]. Whether adding CJC-1295 changes that risk has not been measured.
FDA's page on bulk substances that may raise significant safety risks when compounded now lists CJC-1295 in its nominated-but-withdrawn table, after the nominators withdrew. FDA's posted concerns remain: possible immunogenicity for certain routes, impurity and characterisation problems, limited clinical data, and serious adverse events including increased heart rate and systemic vasodilatory reaction [7]. FDA's briefing also says ConjuChem withdrew CJC-1295 DAC from clinical trials in 2006 after a participant in a phase 2 trial in HIV lipodystrophy (192 enrolled) died. The data were never published, and a link to the drug was neither shown nor excluded [1].
Frequently asked questions
Is CJC-1295 safe to take with rivaroxaban?
Does CJC-1295 affect CYP3A4 or P-glycoprotein?
Does CJC-1295 itself increase bleeding risk?
Is CJC-1295 an approved drug?
References
Show all 8 referencesHide references
- U.S. Food and Drug Administration.
- Drugs@FDA: FDA-Approved Drugs.
- Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1-16.
- Scholz I, Liakoni E, Hammann F, Grafinger KE, Duthaler U, Nagler M, et al. Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. Br J Clin Pharmacol. 2021;87(3):1466-1474.
- Huppertz A, Werntz L, Meid AD, Foerster KI, Burhenne J, Czock D, et al. Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided. Br J Clin Pharmacol. 2018;84(12):2903-2913.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005.